Floatz logo

Serplulimab

Resectable Stage II-IIIa Squamous NSCLC

Shanghai Henlius Biotechmonoclonal_antibodyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

54 Active assets in the Resectable Stage II-IIIa Squamous NSCLC cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB
Tislelizumab
BeOne Medicines
Phase 3BB

View all 50 →

Same molecule, other indications

Serplulimab is also rated in:

ImmunotherapyDormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
Non Small Cell Lung CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →